TCRCure conducts bioinformatics analyses to predict and obtain the neoantigen library from individual patients. By utilizing personalized tumor transcriptome data, TCRCure’s proprietary algorithms are designed to identify high-affinity and highly-presented tumor antigens. Using antigenic peptide stimulation or ex-vivo cancer vaccine strategies, TCRCure can screen for TCRs with functional activity against the tumor antigen. Highly reactive TCRs can be cloned and assembled into TCR-T constructs to generate therapeutic products.

Efficient identification of tumor antigen-specific TCRs is the key to TCR-T technology. TCRCure possesses world-leading technologies in T cell immunotherapies, including TCR repertoire sequencing, high-throughput sequencing-based HLA haplotyping, and high-throughput single-cell sequencing-based T cell transcriptome/repertoire analysis. TCRCure has applied for 5 invention patents, developed a proprietary TCR repertoire analysis algorithm, and formulated management documents, quality manuals and operating procedures. With these technologies, TCRCure is capable of capturing tumor antigen-specific TCRs, cloning and constructing TCR databases, building TCR-T plasmids and virus libraries for given HLA restricted tumor antigens, and providing solutions for next-generation TCR-T immunotherapy.

TCRCure enables robust T cell engineering to achieve enhanced antigen sensitivity, immunosuppression resistance, tumor microenvironment remodeling, memory T cell differentiation and prolonged T cell survival. This platform is integrated into both CAR-T and TCR-T pipelines to advance innovations in T cell immunotherapy.

Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. TCRCure has built multiple cGMP vector production and cell manufacturing laboratories, which consist of three independent functional modules: a viral vector production center, a cell production center and a quality test center. We have established GMP-compliant T cell production, quality control and quality assurance SOP files. With this platform, TCRCure has completed the whole process from viral vector construction to therapeutic product delivery. The Chongqing site was launched in 2017, and the facilities in Los Angeles (US) and Guangzhou (China) will be launched in 2019.